Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
Molecular Cancer Therapeutics
|
March 8, 2017
Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice
Elena Burova, Aynur Hermann, Janelle Waite, et al.
Biorxiv : the Preprint Server for Biology
|
July 9, 2020
Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant
Leonid Yurkovetskiy, Xue Wang, Kristen E Pascal, et al.
Cell
|
September 29, 2020
Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant
Leonid Yurkovetskiy, Xue Wang, Kristen E Pascal, et al.
Glycobiology
|
June 21, 2023
VSIG4 interaction with heparan sulfates inhibits VSIG4-complement binding
Sarah Y Ebstein, Ashique Rafique, Yi Zhou, et al.
Cell Host & Microbe
|
January 28, 2023
Structure of the Inmazeb cocktail and resistance to Ebola virus escape
Vamseedhar Rayaprolu, Benjamin O Fulton, Ashique Rafique, et al.
Plos One
|
May 9, 2020
Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5
Adrianna Latuszek, Yashu Liu, Olav Olsen, et al.
Blood
|
June 11, 2026
Anticoagulation with mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat)
Dan Chalothorn, Aaron Paul Kithcart, Ethan Marin, et al.
Neurobiology of Pain (Cambridge, Mass.)
|
December 15, 2023
Monoclonal antibodies against GFRα3 are efficacious against evoked hyperalgesic and allodynic responses in mouse join pain models but, one of these, REGN5069, was not effective against pain in a randomized, placebo-controlled clinical trial in patients with osteoarthritis pain
Selin Somersan-Karakaya, Kenneth C Turner, Luz Cortes-Burgos, et al.
Scientific Reports
|
August 21, 2019
A novel bispecific antibody platform to direct complement activity for efficient lysis of target cells
Jonathan W Cruz, Ermelinda Damko, Bhavika Modi, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 28, 2019
Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties
Lynn E Macdonald, Karoline A Meagher, Matthew C Franklin, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
Molecular Cancer Therapeutics
|
March 8, 2017
Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice
Elena Burova, Aynur Hermann, Janelle Waite, et al.
Biorxiv : the Preprint Server for Biology
|
July 9, 2020
Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant
Leonid Yurkovetskiy, Xue Wang, Kristen E Pascal, et al.
Cell
|
September 29, 2020
Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant
Leonid Yurkovetskiy, Xue Wang, Kristen E Pascal, et al.
Glycobiology
|
June 21, 2023
VSIG4 interaction with heparan sulfates inhibits VSIG4-complement binding
Sarah Y Ebstein, Ashique Rafique, Yi Zhou, et al.
Cell Host & Microbe
|
January 28, 2023
Structure of the Inmazeb cocktail and resistance to Ebola virus escape
Vamseedhar Rayaprolu, Benjamin O Fulton, Ashique Rafique, et al.
Plos One
|
May 9, 2020
Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5
Adrianna Latuszek, Yashu Liu, Olav Olsen, et al.
Blood
|
June 11, 2026
Anticoagulation with mechanistically distinct FXI/FXIa antibodies amrecibart (REGN9933A2) and cenvacibart (REGN7508Cat)
Dan Chalothorn, Aaron Paul Kithcart, Ethan Marin, et al.
Neurobiology of Pain (Cambridge, Mass.)
|
December 15, 2023
Monoclonal antibodies against GFRα3 are efficacious against evoked hyperalgesic and allodynic responses in mouse join pain models but, one of these, REGN5069, was not effective against pain in a randomized, placebo-controlled clinical trial in patients with osteoarthritis pain
Selin Somersan-Karakaya, Kenneth C Turner, Luz Cortes-Burgos, et al.
Scientific Reports
|
August 21, 2019
A novel bispecific antibody platform to direct complement activity for efficient lysis of target cells
Jonathan W Cruz, Ermelinda Damko, Bhavika Modi, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
December 28, 2019
Kappa-on-Heavy (KoH) bodies are a distinct class of fully-human antibody-like therapeutic agents with antigen-binding properties
Lynn E Macdonald, Karoline A Meagher, Matthew C Franklin, et al.
Page
of 5